loader2
Login Open ICICI 3-in-1 Account

Emcure Pharmaceuticals Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Emcure Pharmaceuticals Ltd. 11 Nov 2025 14:03 PM

Q2FY26 Quarterly Result Announced for Emcure Pharmaceuticals Ltd.

Pharmaceuticals company Emcure Pharmaceuticals announced Q2FY26 results

  • Revenue from operations at Rs 2,270 crore, up 13.4% YoY.
  • EBITDA margins at 19.3% with EBITDA at Rs 439 crore up 15.2% YoY.
  • PAT at Rs 251 crore, up 24.7% YoY.
  • Domestic business sales at Rs 1,031 crore, up 10.6% YoY.
  • International business sales at Rs 1,238 crore, up 15.8% YoY.

Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: “Q2 saw strong performance across all our businesses. We continue to augment our portfolio in all our focus markets though in-licensing and inhouse developments. Novo Nordisk partnership positions us well in the fast-growing obesity segment and gives us an early entry enabling us to shape the market. We remained focus on delivering strong growth along with margin improvement in all our key businesses.”

Result PDF

Pharmaceuticals company Emcure Pharmaceuticals announced Q1FY26 results

  • Revenue from operations at Rs 2,101 crore, up 15.7% YoY.
  • EBITDA margins at 19.2% with EBITDA up 20.1% YoY.
  • PAT at Rs 215 crore, up 41% YoY.
  • Domestic business sales at Rs 995 crore, up 9.4% YoY.
  • International business sales at Rs 1,106 crore, up 22.1% YoY.

Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: “We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets though in-licensing and in-house development. The expanded Sanofi partnership positions us well in the fast growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins. ”

Result PDF

Pharmaceuticals company Emcure Pharmaceuticals announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue from operations at Rs 2,116 crore, up 19.5% YoY
  • EBITDA margins at 18.4% with EBITDA up 25.2% YoY
  • PAT at 197 crore, up 63.0% YoY
  • Domestic business sales at 929 crore, up 24.8% YoY
  • International business sales at 1,187 crore, up 15.6% YoY
  • The Board has proposed a final dividend of Rs 3/- per share

FY25 Financial Highlights:

  • Revenue from Operations stood at Rs 7,896 crore for FY25 compared to Rs 6,658 crore FY24 up 18.6%
  • EBITDA stood at Rs 1,469 crore for FY25 compared to Rs 1,230 crore for FY24 up 19.4%
  • PAT at Rs 707 crore for FY25 compared to Rs 528 crore for FY24 up 34.1%

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said, “Emcure delivered a very strong performance in Q4 with all our businesses segments contributing to growth. Over the past year we have effectively executed our strategies across both Domestic and International markets. On the Domestic side we have expanded our covered market and built a strong product pipeline of upcoming launches. In the International markets we are seeing approvals for our differentiated product offerings. Moving forward, while we continue to drive growth, our key priorities will be improving margins through new product launches and operating efficiencies.”

Result PDF

Pharmaceuticals company Emcure Pharmaceuticals announced Q3FY25 results

  • Revenue: Rs 1,963 crore compared to Rs 1,668 crore during Q3FY24, change 17.7%.
  • EBITDA: Rs 362 crore compared to Rs 294 crore during Q3FY24, change 23.2%.
  • EBITDA Margins: 18.4% for Q3FY25.
  • PAT: Rs 156 crore compared to Rs 120 crore during Q3FY24, change 30.3%.
  • PAT margin: 8.0% for Q3FY25.

Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said: “Emcure witnessed a strong performance in Q3. Our International business is seeing strong performance on back of our differentiated product portolio. On the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portolio. Moving forward, we aim to enhance our organic growth and margins through new product launches and operating efficiencies.”

Result PDF

Pharmaceuticals company Emcure Pharmaceuticals announced Q2FY25 results

  • Revenue from operations at Rs 2,002 crore, up 20.4% YoY and 10.3% QoQ.
  • EBITDA margins at 20.8% with EBITDA up 26.1% YoY and 15.8% QoQ.
  • PAT at 202 crore, up 38.2% YoY with PAT margins at 10.1%.
  • Domestic business sales at 933 crore, up 15.4% YoY.
  • International business sales at 1,069 crore, up 25.0% YoY.

Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said: “Emcure witnessed a strong performance in Q2. We have made significant investments in both our International and Domestic businesses over the past 2 years and the benefits of these efforts are starting to particularly reflect in the growth of our International business. Our recent inorganic additions – Sanofi partnership in India and Mantra acquisition in Canada – are now fully integrated and our focus is now on deriving both revenue and operational synergies. Moving forward, we aim to enhance the margins by leveraging operating efficiencies, while continuing to drive strong growth in both Indian and International markets through new product launches and market share gains.”

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app